Cargando…

Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis

Atopic dermatitis (AD) is a chronic eczematous inflammatory disease that may arise from environmental, genetic, and immunological factors. Despite the efficacy of current treatment options such as corticosteroids, such approaches are mainly focused on symptom relief and may present certain undesirab...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques, Mário Pedro, Varela, Carla, Mendonça, Laura, Cabral, Célia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302414/
https://www.ncbi.nlm.nih.gov/pubmed/37376172
http://dx.doi.org/10.3390/pharmaceutics15061724
_version_ 1785065039250587648
author Marques, Mário Pedro
Varela, Carla
Mendonça, Laura
Cabral, Célia
author_facet Marques, Mário Pedro
Varela, Carla
Mendonça, Laura
Cabral, Célia
author_sort Marques, Mário Pedro
collection PubMed
description Atopic dermatitis (AD) is a chronic eczematous inflammatory disease that may arise from environmental, genetic, and immunological factors. Despite the efficacy of current treatment options such as corticosteroids, such approaches are mainly focused on symptom relief and may present certain undesirable side effects. In recent years, isolated natural compounds, oils, mixtures, and/or extracts have gained scientific attention because of their high efficiency and moderate to low toxicity. Despite their promising therapeutic effects, the applicability of such natural healthcare solutions is somewhat limited by their instability, poor solubility, and low bioavailability. Therefore, novel nanoformulation-based systems have been designed to overcome these limitations, thus enhancing the therapeutic potential, by promoting the capacity of these natural drugs to properly exert their action in AD-like skin lesions. To the best of our knowledge, this is the first literature review that has focused on summarizing recent nanoformulation-based solutions loaded with natural ingredients, specifically for the management of AD. We suggest that future studies should focus on robust clinical trials that may confirm the safety and effectiveness of such natural-based nanosystems, thus paving the way for more reliable AD treatments.
format Online
Article
Text
id pubmed-10302414
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103024142023-06-29 Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis Marques, Mário Pedro Varela, Carla Mendonça, Laura Cabral, Célia Pharmaceutics Review Atopic dermatitis (AD) is a chronic eczematous inflammatory disease that may arise from environmental, genetic, and immunological factors. Despite the efficacy of current treatment options such as corticosteroids, such approaches are mainly focused on symptom relief and may present certain undesirable side effects. In recent years, isolated natural compounds, oils, mixtures, and/or extracts have gained scientific attention because of their high efficiency and moderate to low toxicity. Despite their promising therapeutic effects, the applicability of such natural healthcare solutions is somewhat limited by their instability, poor solubility, and low bioavailability. Therefore, novel nanoformulation-based systems have been designed to overcome these limitations, thus enhancing the therapeutic potential, by promoting the capacity of these natural drugs to properly exert their action in AD-like skin lesions. To the best of our knowledge, this is the first literature review that has focused on summarizing recent nanoformulation-based solutions loaded with natural ingredients, specifically for the management of AD. We suggest that future studies should focus on robust clinical trials that may confirm the safety and effectiveness of such natural-based nanosystems, thus paving the way for more reliable AD treatments. MDPI 2023-06-14 /pmc/articles/PMC10302414/ /pubmed/37376172 http://dx.doi.org/10.3390/pharmaceutics15061724 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Marques, Mário Pedro
Varela, Carla
Mendonça, Laura
Cabral, Célia
Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis
title Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis
title_full Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis
title_fullStr Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis
title_full_unstemmed Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis
title_short Nanotechnology-Based Topical Delivery of Natural Products for the Management of Atopic Dermatitis
title_sort nanotechnology-based topical delivery of natural products for the management of atopic dermatitis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302414/
https://www.ncbi.nlm.nih.gov/pubmed/37376172
http://dx.doi.org/10.3390/pharmaceutics15061724
work_keys_str_mv AT marquesmariopedro nanotechnologybasedtopicaldeliveryofnaturalproductsforthemanagementofatopicdermatitis
AT varelacarla nanotechnologybasedtopicaldeliveryofnaturalproductsforthemanagementofatopicdermatitis
AT mendoncalaura nanotechnologybasedtopicaldeliveryofnaturalproductsforthemanagementofatopicdermatitis
AT cabralcelia nanotechnologybasedtopicaldeliveryofnaturalproductsforthemanagementofatopicdermatitis